Skip to main content
9 search results for:

GIP/GLP-1 agonists 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 07-20-2023 | Type 2 diabetes | News | Article

    Triple agonist shows promise for both glycemic and weight control

    The researchers note that “participants were still losing weight” at time of reporting and highlight that “[t]his magnitude of bodyweight reduction has not been reported so far in any other phase 2 or 3 trials testing weekly GLP-1 or GIP and GLP-1 receptor agonists in people with type 2 diabetes.”

  2. 07-14-2023 | Type 2 diabetes | News | Article

    Cagrilintide plus semaglutide shows dual benefit in type 2 diabetes

    “Our phase 2 clinical trial is the first study to report efficacy and safety data for treatment with the combination of a GLP-1 receptor agonist and an amlylin analogue in participants with type 2 diabetes,” Juan Frias (Velocity Clinical Research, Los Angeles, California, USA) and colleagues say in The Lancet .

  3. 07-21-2022 | Sotagliflozin | News | Article

    Sotagliflozin effects differ from empagliflozin only at breakfast

    However, they highlight the effect of the two SGLT inhibitors, particularly sotagliflozin, on GIP levels, noting that recent research suggests that GIP inhibition may be cardioprotective, contrary to the development of GLP-1/GIP co-agonists to treat type 2 diabetes.

  4. 05-20-2022 | Cardiovascular outcomes | News | Article

    Survival time analysis shows CV benefits of GLP1 receptor agonists

    Glucagon-like peptide-1 receptor agonists may delay the incidence of major adverse cardiovascular events by an average of 0.6 months over a 4-year period in people with type 2 diabetes, meta-analysis data suggest.

  5. 09-01-2022 | Metformin | News | Article

    People with type 2 diabetes and CKD missing out on renoprotective drugs

    Glucagon-like peptide-1 receptor agonist (GLP-1RA) use was below 5% throughout the study period in people with and without CKD.

  6. 10-14-2020 | Type 2 diabetes | Editorial | Article

    Tirzepatide: A new challenger for type 2 diabetes management?

    What does the future hold for the novel agent tirzepatide, a GIP/GLP-1 co-agonist? John Wilding examines what we know so far.

  7. 06-26-2021 | ADA 2021 | News | Article

    SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

    The dual GIP and GLP-1 receptor agonist tirzepatide has “potent glucose-lowering effects towards near-normal ranges,” and also induces significant weight loss in people with type 2 diabetes, say the SURPASS-1 investigators.

  8. 10-04-2018 | GLP-1 agonists | News | Article

    Promising phase II data for dual GIP and GLP-1 receptor agonist

    A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

  9. 09-13-2017 | GLP-1 agonists | EASD 2017 | Article

    Incretins research update

    The men were given infusions of GIP, GLP-1, both, or neither over 270 minutes on separate study days in a randomized order.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.